Cargando…

Corrigendum: Identification of Leishmania donovani Topoisomerase 1 inhibitors via intuitive scaffold hopping and bioisosteric modification of known Top 1 inhibitors

Detalles Bibliográficos
Autores principales:	Mamidala, Rajinikanth, Majumdar, Papiya, Jha, Kunal Kumar, Bathula, Chandramohan, Agarwal, Rahul, Chary, M. Thirumala, Majumder, Hemanta K., Munshi, Parthapratim, Sen, Subhabrata
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Corrigenda
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4913756/ https://www.ncbi.nlm.nih.gov/pubmed/27323004 http://dx.doi.org/10.1038/srep28120

Ejemplares similares

Identification of Leishmania donovani Topoisomerase 1 inhibitors via intuitive scaffold hopping and bioisosteric modification of known Top 1 inhibitors
por: Mamidala, Rajinikanth, et al.
Publicado: (2016)

Isobenzofuranone derivative JVPH3, an inhibitor of L. donovani topoisomerase II, disrupts mitochondrial architecture in trypanosomatid parasites
por: Chowdhury, Somenath Roy, et al.
Publicado: (2018)

Corrigendum: RILP interacts with HOPS complex via VPS41 subunit to regulate endocytic trafficking
por: Lin, Xiaosi, et al.
Publicado: (2015)

‘LeishMan’ topoisomerase I: an ideal chimera for unraveling the role of the small subunit of unusual bi-subunit topoisomerase I from Leishmania donovani
por: Ganguly, Agneyo, et al.
Publicado: (2006)

ATP independent type IB topoisomerase of Leishmania donovani is stimulated by ATP: an insight into the functional mechanism
por: Sengupta, Souvik, et al.
Publicado: (2011)

Identification of a Functional Type IA Topoisomerase, LdTopIIIβ, from Kinetoplastid Parasite Leishmania donovani
por: Banerjee, Bijoylaxmi, et al.
Publicado: (2011)

Development of Derivatives of 3, 3′-Diindolylmethane as Potent Leishmania donovani Bi-Subunit Topoisomerase IB Poisons
por: Roy, Amit, et al.
Publicado: (2011)

Characterization of the DNA-binding domain and identification of the active site residue in the ‘Gyr A’ half of Leishmania donovani topoisomerase II
por: Sengupta, Tanushri, et al.
Publicado: (2005)

Retraction of ‘Functional dissection of the C‐terminal domain of type II DNA topoisomerase from the kinetoplastid hemoflagellate Leishmania donovani’
por: Sengupta, Tanushri, et al.
Publicado: (2021)

Natural Product Inspired Novel Indole based Chiral Scaffold Kills Human Malaria Parasites via Ionic Imbalance Mediated Cell Death
por: Dangi, Poonam, et al.
Publicado: (2019)

Design and Synthesis of Bioisosteres of Acylhydrazones as Stable Inhibitors of the Aspartic Protease Endothiapepsin
por: Jumde, Varsha R., et al.
Publicado: (2018)

The lignan niranthin poisons Leishmania donovani topoisomerase IB and favours a Th1 immune response in mice
por: Chowdhury, Sayan, et al.
Publicado: (2012)

Differential induction of Leishmania donovani bi-subunit topoisomerase I–DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I
por: Das, Benu Brata, et al.
Publicado: (2006)

Corrigendum: Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases
por: Basarab, Gregory S., et al.
Publicado: (2015)

Corrigendum to: Off‐target inhibition by active site‐targeting SHP2 inhibitors
por: Tsutsumi, Ryouhei, et al.
Publicado: (2019)

Corrigendum: Soybean-derived Bowman-Birk Inhibitor (BBI) Inhibits HIV Replication in Macrophages
por: Ma, Tong-Cui, et al.
Publicado: (2016)

Corrigendum: First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor
Publicado: (2022)

Corrigendum: Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738
por: Checkley, Stephen, et al.
Publicado: (2016)

Corrigendum: Mechanistic analysis of a synthetic inhibitor of the Pseudomonas aeruginosa LasI quorum-sensing signal synthase
por: Lidor, O., et al.
Publicado: (2016)

Corrigendum: Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication
por: Magri, Andrea, et al.
Publicado: (2016)

Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
por: Chabon, Jacob J., et al.
Publicado: (2016)

Corrigendum to “Individual and common inhibitors of coronavirus and picornavirus main proteases” [FEBS Lett. 583 (2009) 549–555]
por: Kuo, Chih-Jung, et al.
Publicado: (2009)

Imidazolines as Non-Classical Bioisosteres of N-Acyl Homoserine Lactones and Quorum Sensing Inhibitors
por: Reyes-Arellano, Alicia, et al.
Publicado: (2012)

A novel library of -arylketones as potential inhibitors of α-glucosidase: Their design, synthesis, in vitro and in vivo studies
por: Luthra, Tania, et al.
Publicado: (2017)

Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors
por: Cayrol, Florencia, et al.
Publicado: (2017)

Corrigendum: The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells
por: Wang, Xin, et al.
Publicado: (2016)

Corrigendum: Transcriptional repression of SIRT1 by protein inhibitor of activated STAT 4 (PIAS4) in hepatic stellate cells contributes to liver fibrosis
por: Sun, Lina, et al.
Publicado: (2016)

Corrigendum: PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer
por: Song, Wei, et al.
Publicado: (2017)

New Compounds with Bioisosteric Replacement of Classic Choline Kinase Inhibitors Show Potent Antiplasmodial Activity
por: Aguilar-Troyano, Francisco José, et al.
Publicado: (2021)

Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
por: Xu, Jianlin, et al.
Publicado: (2016)

PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage
por: Das, Benu Brata, et al.
Publicado: (2014)

Bioisosteric Modification of To042: Synthesis and Evaluation of Promising Use‐Dependent Inhibitors of Voltage‐Gated Sodium Channels
por: Milani, Gualtiero, et al.
Publicado: (2021)

Bioisosteric similarity of drugs in virtual screening
por: Hutter, Michael C, et al.
Publicado: (2010)

Bioisosteric Matrices for Ligands of Serotonin Receptors
por: Warszycki, Dawid, et al.
Publicado: (2015)

Developments in Non-Intercalating Bacterial Topoisomerase Inhibitors: Allosteric and ATPase Inhibitors of DNA Gyrase and Topoisomerase IV
por: Grossman, Scott, et al.
Publicado: (2023)

Development of Non-Ethoxypropanoic Acid Type Cryptochrome Inhibitors with Circadian Molecular Clock-Enhancing Activity by Bioisosteric Replacement
por: Jeong, Yong Uk, et al.
Publicado: (2021)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

Corrigendum to Nishank Jain, Milind A. Phadnis, Suzanne L. Hunt, Junqiang Dai, Theresa I. Shireman, Clayton L. Davis, Jawahar L. Mehta, Rafia S. Rasu and S. Susan Hedayati. “Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis”. Kidney Int Rep. 2021;6(9):2381-2391.
Publicado: (2022)

The Structural Features of Novel Bacterial Topoisomerase Inhibitors That Define Their Activity on Topoisomerase IV
por: Kokot, Maja, et al.
Publicado: (2022)

Discovery of high affinity inhibitors of Leishmania donovani N-myristoyltransferase
por: Rackham, Mark D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_cjh33633naqevjfn9cruqb4lvj